×
To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.
Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.
As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.
DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.
Female patient, age 39, CML-CP, int ELTS, diagnosed 3 yrs ago, no high-risk features, on dasatinib 100mg in stable MMR for 18 months. No previous pregnancies. Has read the new ELN 25 recommendations and the NCCN 26 guidelines. Should the advice be to try to conceive on TKI, and stop when pregnancy is confirmed?
The answer is yes — we prefer not to risk a relapse while trying to conceive. Since most relapses occur within 3–6 months, and the first 3 months of pregnancy carry the greatest teratogenic risk, we recommend stopping the TKI at the time of the first positive pregnancy test (around 3–5 weeks of gestation). Of course, the patient should be advised to monitor for pregnancy carefully so she can discontinue the TKI promptly.
We also suggest initiating IFN once pregnancy is confirmed, without waiting for an increase in transcript levels, as it is unlikely she will maintain MMR after only 18 months of treatment. Her age is borderline, so I would recommend moving forward without delaying further.
If the patient, given her advanced age for a first pregnancy, does not wish to continue waiting to achieve a deeper molecular response, which would always represent a safer scenario, the proposed approach can be considered acceptable: to continue dasatinib therapy, perform regular pregnancy testing, and discontinue treatment immediately upon the first positive result.
We had one lady who conceived while on Dasatinib with disastrous consequences (macerated baby) etc., and I will definitely recommend not to try to conceive on Dasatinib, and best option is interferon, although we had successful pregnancies with Imatinib.
I would like to know if the patient is in deep molecular remission or not, and if yes, for how long? My advice would be to wait for one or preferably two more years before attempting pregnancy. The option of embryo freezing can also be considered. However, if the patient is adamant about conceiving right away, then the strategy suggested by you could be considered, with close monitoring of bcr/abl transcripts, and avoiding TKI exposure during the 1st trimester of pregnancy.
Far be it from me to disagree with the pregnancy experts who have commented here. The two issues are firstly, how deep is MMR? The likelihood of rebound of disease on stopping TKI if the response is in the 0.1% IS range is very high. Secondly, IFN takes a while to capture once started. The biggest risk of TKI related teratogenicity is in the first trimester, safest in the third and variable in the second. Let me toss an idea into the discussion. Why not start IFN immediately while still on TKI, then attempt pregnancy and stop TKI immediately on detecting pregnancy while doing "routine" pregnancy testing. There is some evidence from the German trials that adding IFN to a TKI may be beneficial and having it on board may (wishfully thinking?) reduce the chances of rebound. IFN as well is sage in pregnancy, and as well, there is evidence that it may help with fetal retention (the placenta secretes IFNs) at least in the thrombocytosis literature.
This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.View our Privacy Policy